The stock price of Merck surged 8% to levels of $81 on Friday, Oct 1, after the company announced that its Molnupiravir pill reduces the risk of hospitalization and death by 50% for patients with mild to moderate Covid-19. The data is so encouraging that Merck has now stopped new patient enrollments
